Fundamental analysis · SEC EDGAR · TTM through 30/06/2026
HIMS · NYSE · Healthcare
Fundamental quality
55
out of 100
Hims & Hers Health, Inc. is in full growth mode but not yet profitable: revenue is growing strongly (68.1% a year), but it doesn't translate into earnings yet. On fundamental quality it scores 55 out of 100, profiling it as a company of reasonable quality. Its weakest area is its financial strength (net debt 9.06× EBITDA). Whether it's cheap or expensive depends on the current price, which you can compute in the tool.
Hims & Hers is a consumer telehealth platform: online consultations and home-delivered medications by subscription, in areas like sexual health, hair loss, mental health and weight loss. Its strength is brand and direct-to-consumer marketing.
Revenue growth: 68.1%
Net margin: -5.5% · ROE: -43.8%
Net debt/EBITDA: 9.06x · FCF: 2.4%
Source: SEC EDGAR · TTM through 30/06/2026
The score combines growth, profitability and financial strength. Here its growth weighs in its favor, while its financial strength drags it down the most.
Percentile against the other 57 Healthcare companies in our coverage: how far it beats them on each metric (100 = best in sector).
Computed from the daily dataset scores. A high percentile places the company among the best in its sector on that metric; it is not a buy recommendation.
Key concepts
What do these metrics mean? Fundamental analysis · What is the P/E · What is EPS · What is ROE · Net & gross margin · Free cash flow
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2020 | 149 | -18 | — | -27 |
| 2021 | 272 | -108 | — | -72 |
| 2022 | 527 | -66 | -34 | -47 |
| 2023 | 872 | -24 | 47 | -97 |
| 2024 | 1,477 | 126 | 198 | -221 |
| 2025 | 2,348 | 128 | 57 | -229 |
Between 2020 and 2025, revenue went from $149M to $2,348M (+1478%) and net income went from -$18M to $128M (+809%).
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
Latest results
Figures for the half-year ended June 30, 2026, versus the half-year ended June 30, 2025 (SEC filings):
Compared with the previous close (March 31, 2026), this is what moved in its accounts:
Automatic comparison between the two most recent periods filed with the SEC. One quarter doesn't make a trend: read it alongside the historical evolution above.
This company doesn't pay a dividend: it reinvests all its earnings back into the business.
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
Is Hims & Hers Health, Inc. cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Is Hims & Hers Health, Inc. a good company to invest in?
In terms of business quality, Hims & Hers Health, Inc. scores 55 out of 100 in our analysis, placing it as a company of reasonable quality. That said, this isn't a recommendation: whether it's a good investment also depends on its current price and your goals.
Is Hims & Hers Health, Inc. a profitable company?
Over the last twelve months, no: Hims & Hers Health, Inc. posts a negative net margin (-5.5%).
Does Hims & Hers Health, Inc. have a lot of debt?
Yes, its leverage is high: net debt is 9.06 times its EBITDA.
Is Hims & Hers Health, Inc. growing?
Its revenue has grown 68.1% annualized in recent years, and without interruption since 2020.
Does Hims & Hers Health, Inc. generate cash?
Yes. It converts about 2.4% of its revenue into free cash flow.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
More Healthcare companies
AbbVie (ABBV) · Merck (MRK) · Thermo Fisher Scientific (TMO) · Abbott Laboratories (ABT) · Intuitive Surgical (ISRG) · Pfizer (PFE) · see more →
The best Healthcare stocks by our model →
Compare Hims & Hers Health, Inc. with 500+ companies in the screener →
Who's behind the methodology and model · how the score is computed
Data: see Hims & Hers Health, Inc.'s filings on EDGAR
Spotted a figure that looks wrong? Report it and we'll review it.